Is It Cost-Effective To Increase Aspirin Use in Outpatient Settings for Primary or Secondary Prevention? Simulation Data from the REACH Registry Australian Cohort
MetadataShow full item record
Aims: To describe aspirin use in primary and secondary prevention and to determine the incremental costs-effectiveness ratio (ICER) per life year gain (LYG) of aspirin use among subjects with, or at high risk of atherothrombotic disease. Design and Subjects: To project the cost-effectiveness of aspirin over 5 years of follow-up, a Markov state transition model was developed with yearly cycles and the following health states: "Alive" (post-CAD) and "Dead." The model compared current coverage observed among 2361 subjects using the prospective Australian subset of Reduction of Atherothrombosis for continued Health (REACH) registry, and hypothetical situation whereby all subjects assumed to be treated. Costs were calculated based on the Australian government reimbursed data for 2010. Main outcome measures: ICER per LYG for increased use of aspirin. Results: The use of aspirin in current group varied from 67% to 70%. The base-case analysis showed that increasing aspirin use among subjects with existing CAD in outpatient settings was cost saving, while increasing use of aspirin in primary prevention equated to an ICER of AUD 7126 per LYG. Conclusion: Among subjects with existing CAD aspirin use was shown to be a dominant choice of treatment. However, among patients without existing cardiovascular disease (primary prevention), increased uptake of aspirin was cost effective but with uncertain benefit, with two hemorrhagic bleeding events occurring for every life saved. © 2011 Blackwell Publishing Ltd.
Showing items related by title, author, creator and subject.
Age-related macular degeneration in a randomized controlled trial of low-dose aspirin: Rationale and study design of the ASPREE-AMD studyRobman, L.; Guymer, R.; Woods, R.; Ward, S.; Wolfe, R.; Phung, J.; Hodgson, L.; Makeyeva, G.; Aung, K.; Gilbert, T.; Lockery, J.; Le-Pham, Y.; Orchard, S.; Storey, E.; Abhayaratna, W.; Reid, D.; Ernst, M.; Nelson, M.; Reid, Christopher; McNeil, J. (2017)Purpose: Although aspirin therapy is used widely in older adults for prevention of cardiovascular disease, its impact on the incidence, progression and severity of age-related macular degeneration (AMD) is uncertain. The ...
Using large-scale linkage data to evaluate the effectiveness of a national educational program on antithrombotic prescribing and associated stroke prevention in primary careLiu, Z.; Moorin, Rachael; Worthington, J.; Tofler, G.; Bartlett, M.; Khan, R.; Zuo, Y. (2016)Background-—The National Prescribing Service (NPS) MedicineWise Stroke Prevention Program, which was implemented nationally in 2009–2010 in Australia, sought to improve antithrombotic prescribing in stroke prevention using ...
Predicting the impact of polypill use in a metabolic syndrome population: An effectiveness and cost-effectiveness analysisZomer, E.; Owen, A.; Magliano, D.; Ademi, Z.; Reid, Christopher; Liew, D. (2013)Background: Individuals with metabolic syndrome (MetS) are at increased risk of cardiovascular disease (CVD), often requiring combination drug therapy for control of risk factors and subsequent risk reduction. This study ...